Meralys (Xylometazoline Hydrochloride)

Xylometazoline Hydrochloride is a selective alpha‑adrenergic agonist. When applied to the nasal mucosa, it stimulates alpha‑adrenergic receptors on blood vessels, causing vasoconstriction. This reduces blood flow and edema in the nasal passages, leading to decreased congestion and easier breathing.

The dosage of Meralys is determined by the prescribing healthcare professional. Typically, a few sprays per nostril are administered, but the exact number of sprays, frequency, and duration should follow the prescriber’s instructions and the product label.

Safety data for Xylometazoline Hydrochloride in pregnancy or lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should consult their physician before using Meralys to weigh potential benefits against any unknown risks.

To order Meralys, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Meralys contains Xylometazoline, a selective alpha‑adrenergic agonist, which provides rapid decongestion similar to other OTC agents like oxymetazoline. Compared with older compounds, Xylometazoline often has a slightly longer duration of action and a comparable safety profile when used as directed.

Store Meralys at room temperature, away from direct sunlight and moisture. Keep the spray in its original packaging to protect the nozzle and maintain sterility. Do not freeze the product, and ensure the cap is tightly closed when not in use.

Meralys is administered as a nasal spray. The user tilts the head slightly forward, inserts the nozzle into one nostril, and sprays the prescribed number of sprays while breathing in gently. The process is repeated in the other nostril if required, following the prescriber’s guidance.

Serious risks, though rare, include nasal septum perforation, significant hypertension, and rebound congestion after prolonged use. An allergic reaction such as rash, itching, or swelling may also occur. Users should discontinue the spray and seek medical attention if any of these events arise.

Meralys should be avoided by individuals with known hypersensitivity to Xylometazoline or any component of the formulation. It is also contraindicated in patients using MAO inhibitors, those with severe hypertension, or anyone advised by a healthcare professional to refrain from nasal decongestants.